Vanda Pharmaceuticals (VNDA) Long-Term Deferred Tax (2010 - 2025)

Vanda Pharmaceuticals has disclosed Long-Term Deferred Tax across 9 years of filings, most recently posting $103.1 million for Q3 2025.

• Long-Term Deferred Tax for Q3 2025 came in at $103.1 million, up 29.88% year-over-year; the trailing twelve-month figure through Sep 2025 was $103.1 million (up 29.88% YoY), and the FY2024 annual result was $81.4 million, up 8.59% from the prior year.
• Long-Term Deferred Tax came in at $103.1 million for Q3 2025 at Vanda Pharmaceuticals, up from $97.1 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $103.1 million in Q3 2025 to a low of $67.8 million in Q3 2023.
• The 5-year median for Long-Term Deferred Tax is $75.3 million (2024), against an average of $78.4 million.
• Across the five-year window, Long-Term Deferred Tax retreated 11.89% in 2022 and grew 29.88% in 2025, its largest moves.
• Vanda Pharmaceuticals' Long-Term Deferred Tax stood at $74.9 million in 2021, then decreased by 1.12% to $74.0 million in 2022, then advanced by 1.3% to $75.0 million in 2023, then advanced by 8.59% to $81.4 million in 2024, then gained by 26.56% to $103.1 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $103.1 million (Q3 2025), $97.1 million (Q2 2025), and $89.1 million (Q1 2025), per Business Quant data.